News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medical Device Firm TherOx Files for $100 Million IPO


9/5/2008 6:45:13 AM

IRVINE, Calif., Sept. 4 /PRNewswire/ -- TherOx, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock.

Citigroup Global Markets Inc. and UBS Investment Bank are acting as joint book-running managers for the offering with Cowen and Company, LLC and Wachovia Capital Markets, LLC acting as co-managers. The number of shares to be offered by TherOx and the price range for its shares have yet to be determined.

The offering of common stock will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from either Citigroup Global Markets Inc., Brooklyn Army Terminal, 140 58th Street, Brooklyn, New York 11220, Attn: Prospectus Department or UBS Investment Bank, Attn: Prospectus Department, 299 Park Avenue, New York, New York 10171.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell nor the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of the securities under the securities laws of any such state or jurisdiction.

About TherOx, Inc.

TherOx is a medical device company that is focused on designing, developing and marketing products that implement its proprietary Supersaturated Oxygen System to salvage heart muscle in acute heart attack patients. TherOx's Supersaturated Oxygen System has not yet received FDA approval and is currently limited by United States law to investigational use only.

CONTACT: Kevin T. Larkin, President and Chief Executive Officer, or
Shelley B. Thunen, Chief Financial Officer, both of TherOx, Inc.,
+1-949-757-1999


Read at BioSpace.com
Read at Reuters

comments powered by Disqus
TherOx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES